Fenghuang Zhan

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. pmc Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia
    Eun Sung Park
    Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    BMC Genomics 8:302. 2007
  2. pmc CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
    Blood 109:4995-5001. 2007
  3. pmc Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
    Lijuan Chen
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 115:61-70. 2010
  4. pmc The molecular classification of multiple myeloma
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 108:2020-8. 2006
  5. pmc RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
    Siqing Wang
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR, USA
    Blood 114:600-7. 2009
  6. ncbi request reprint Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival
    Yun Ge
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 133:83-92. 2006
  7. pmc The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
    Simona Colla
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 109:4470-7. 2007
  8. ncbi request reprint A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    John D Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2276-84. 2007
  9. pmc Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatio
    Ichiro Hanamura
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St 776, Little Rock, AR 72205, USA
    Blood 108:1724-32. 2006
  10. pmc Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2106-11. 2007

Detail Information

Publications47

  1. pmc Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia
    Eun Sung Park
    Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    BMC Genomics 8:302. 2007
    ....
  2. pmc CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
    Blood 109:4995-5001. 2007
    ....
  3. pmc Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
    Lijuan Chen
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 115:61-70. 2010
    ..Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib...
  4. pmc The molecular classification of multiple myeloma
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 108:2020-8. 2006
    ..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature...
  5. pmc RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
    Siqing Wang
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR, USA
    Blood 114:600-7. 2009
    ..These findings provide a rationale for RA-based therapy in aggressive RARalpha2(+) MM...
  6. ncbi request reprint Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival
    Yun Ge
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 133:83-92. 2006
    ..Our results indicate that FAP is critical for the interaction of MM cells with the BM microenvironment--a potential therapeutic target in myeloma...
  7. pmc The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
    Simona Colla
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 109:4470-7. 2007
    ..We conclude that specific strategies to modulate persistent activation of the JNK pathway may be beneficial in preventing disease progression and treating myeloma-associated bone disease by inhibiting DKK1 expression...
  8. ncbi request reprint A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    John D Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2276-84. 2007
    ..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions...
  9. pmc Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatio
    Ichiro Hanamura
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St 776, Little Rock, AR 72205, USA
    Blood 108:1724-32. 2006
    ..027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis...
  10. pmc Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2106-11. 2007
    ..We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth...
  11. ncbi request reprint The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
    Erming Tian
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, College of Medicine, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    N Engl J Med 349:2483-94. 2003
    ..Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both...
  12. pmc Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
    Mol Cancer Ther 8:2616-24. 2009
    ....
  13. pmc Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 109:1692-700. 2007
    ..01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias...
  14. ncbi request reprint Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
    Alessandro D Santin
    Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Virology 331:269-91. 2005
    ....
  15. ncbi request reprint Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
    John Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 101:3849-56. 2003
    ....
  16. pmc An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
    Wei Xiong
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:4235-46. 2008
    ..These data suggest that loss of TP53 expression in MM confers high risk and probably results in the deregulation of a novel set of MM-specific TP53-target genes. TP53 target gene specificity may be unique to different cell lineages...
  17. ncbi request reprint The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype
    Clive S Zent
    Division of Hematology Oncology, Central Arkansas Healthcare System and University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
    Leuk Res 27:765-74. 2003
    ..CLL and MM differentially expressed 18% of 130 apoptosis related genes, suggesting differences in mechanisms of cell survival...
  18. pmc Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:802-11. 2007
    ..These myeloma cell lines and the procedures used for their establishment provide essential tools for studying myeloma biology and therapy...
  19. ncbi request reprint Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development
    Fenghuang Zhan
    Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 101:1128-40. 2003
    ..000 09). MM1 showed no significant linkage with normal cell types studied. Thus, genes whose expression is linked to distinct transitions in late-stage B-cell differentiation can be used to classify MM...
  20. ncbi request reprint Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma
    Susann Szmania
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Immunother 30:847-54. 2007
    ..MAGE-A3 immunization may be a useful adjunct to high dose melphalan-based peripheral blood stem cell transplant, providing a new therapeutic option for high-risk MM...
  21. ncbi request reprint Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling
    Fenghuang Zhan
    Donna D and m Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Hematol 40:308-20. 2003
    ..Here we discuss recent progress made in the development of molecular-based diagnostics and prognostics for MM through the dissection of the transcriptome of PCs from healthy individuals and patients with MM and other PC dyscrasias...
  22. ncbi request reprint Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Blood 99:1745-57. 2002
    ..Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM...
  23. doi request reprint Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma
    Amy Heerema-McKenney
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, USA
    Am J Clin Pathol 133:265-70. 2010
    ..Most cases share a common GEP signature dominated by hyperexpression of cyclin D1 or cyclin D3 genes, with increased expression of the B-cell genes CD20 and VPREB3...
  24. ncbi request reprint High heparanase activity in multiple myeloma is associated with elevated microvessel density
    Thomas Kelly
    Departments of Pathology, Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Cancer Res 63:8749-56. 2003
    ....
  25. ncbi request reprint A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
    Madhumita Santra
    Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 101:2374-6. 2003
    ..These data indicate that the t(4;14)(p16;q32) and loss of FGFR3 occurred at a very early stage and suggest that activation of MMSET, not FGFR3, may be the critical transforming event of this recurrent translocation...
  26. ncbi request reprint Gene expression profiling and multiple myeloma
    John Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Best Pract Res Clin Haematol 18:537-52. 2005
    ..Expression profiling has also led to the identification of a number of new therapeutic targets not only in myeloma cell survival but also in the pathogenesis of the osteolysis which is a hallmark of this disease...
  27. pmc NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301 West Markham, no 776, Little Rock, AR 72205, USA
    Blood 105:3939-44. 2005
    ..The pool of NY-ESO-1-specific cytotoxic T cells expands easily on NY-ESO-1 peptide stimulation and is functionally active. NY-ESO-1 should therefore be an ideal tumor target antigen for immunotherapy of patients with poor-prognosis MM...
  28. ncbi request reprint Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Int J Cancer 112:14-25. 2004
    ..NOVA. These results, obtained with highly purified primary cultures of ovarian cancer, highlight important molecular features of OSPC and may provide a foundation for the development of new type-specific therapies against this disease...
  29. ncbi request reprint CGO: utilizing and integrating gene expression microarray data in clinical research and data management
    Klaus Bumm
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics and Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bioinformatics 18:327-8. 2002
    ....
  30. ncbi request reprint Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
    Jeffrey Haessler
    Cancer Research and Biostatistics, Seattle, Washington, USA
    Clin Cancer Res 13:7073-9. 2007
    ..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma...
  31. ncbi request reprint CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease
    Jeroen E J Guikema
    Department of Cell Biology, Histology and Immunology Section, University Hospital, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Br J Haematol 121:36-43. 2003
    ..In conclusion, CD27 is heterogeneously expressed on MM PC and loss of CD27 expression might have prognostic value in MM...
  32. doi request reprint CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
    Eric D Hsi
    Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Cancer Res 14:2775-84. 2008
    ....
  33. pmc Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma
    Bart Burington
    Cancer Research and Biostatistics, Seattle, Washington, USA
    Clin Cancer Res 14:4821-9. 2008
    ..Genes whose drug-altered expression were found to be related to survival may point to molecular switches related to response and/or resistance to different classes of drugs...
  34. ncbi request reprint Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation
    Karin Tarte
    INSERM U475, 99, Montpellier, France
    Blood 102:592-600. 2003
    ..These data should help to better understand the molecular events that regulate commitment to a PC fate, mediate PC maintenance in survival niches, and could facilitate PC immortalization in plasma cell dyscrasias...
  35. ncbi request reprint Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts
    Karin Tarte
    Unité de Thérapie Cellulaire, CHU Montpellier, France
    Blood 100:1113-22. 2002
    ..In addition, the comparison of gene expression between plasmablastic cells and B cells provides a new and powerful tool to identify genes specifically involved in normal plasma cell differentiation...
  36. ncbi request reprint High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
    Daniel R Carrasco
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Cell 9:313-25. 2006
    ....
  37. ncbi request reprint RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma
    Christopher A Maxwell
    Department of Medical Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada
    Blood 104:1151-8. 2004
    ..The RHAMM-exon4/RHAMMFL ratio in diagnostic bone marrow samples (n=101, Alberta) is an independent prognostic factor. Thus, expression and splicing of RHAMM are important molecular determinants of disease severity in MM...
  38. pmc Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
    Unn Merete Fagerli
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway
    Blood 111:806-15. 2008
    ..In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells...
  39. ncbi request reprint ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma
    Atsushi Suzuki
    Cancer Physiology Project, National Cancer Center Research Institute East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Oncogene 24:6936-44. 2005
    ..Based on results, we conclude that ARK5 is a transcriptional target of the Large-MAF family through MARE sequence and that ARK5 may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas...
  40. pmc Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
    P Leif Bergsagel
    Mayo Clinic Scottsdale, Comprehensive Cancer Center and Division of Hematology Oncology, Scottsdale, AZ, USA
    Blood 106:296-303. 2005
    ..However, despite subsequent progression events, these groups have differing gene expression profiles and also significant differences in the prevalence of bone disease, frequency at relapse, and progression to extramedullary tumor...
  41. ncbi request reprint Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
    George Mulligan
    Clinical Research Translational Medicine, Millennium Pharmaceuticals Inc, 40 Landsdowne Street, Cambridge, MA 02139, USA
    Blood 109:3177-88. 2007
    ..Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents...
  42. ncbi request reprint Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis
    Yang Yang
    Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Biol Chem 282:13326-33. 2007
    ..These results reveal a new mechanism by which heparanase promotes an aggressive tumor phenotype and suggests that heparanase and syndecan-1 act synergistically to fine tune the tumor microenvironment and ensure robust tumor growth...
  43. pmc Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma
    Jianfei Qian
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:1587-94. 2007
    ..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM...
  44. pmc Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma
    Christina M Annunziata
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Cancer Cell 12:115-30. 2007
    ..These data demonstrate that addiction to the NF-kappaB pathway is frequent in myeloma and suggest that IKKbeta inhibitors hold promise for the treatment of this disease...
  45. pmc High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
    Fenghuang Zhan
    Blood 111:968-9. 2008
  46. ncbi request reprint Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray
    Pei Lin
    Department of Pathology, University of Arkansas for Medical Science, USA
    Mod Pathol 17:1217-22. 2004
    ..We conclude that CD20-positive myelomas expressing PAX5/BSAP can present as a diagnostic pitfall mimicking B-cell neoplasms with plasmacytoid differentiation...
  47. ncbi request reprint Smoldering multiple myeloma
    H Keshava Prasad
    N Engl J Med 357:1048; author reply 1049-50. 2007